On June 25, 2019, in the offices of the National Assembly in Paris, François Ruffin, deputy , and Cyril Pocréaux , journalist, author of the book "A deputy at Big Pharma" and substantive articles on the Sanofi laboratory, were at the initiative of this round table to bring together several representatives of associations of victims of drugs or medical devices
As no founding member of the association was able to go to this meeting (problem of train line cut following storm for the president whose presence he was planned!), Our legal advisor, Maitre Charles Joseph-Oudin represented us and exposed the following:
- the problem of meningiomas due to drugs, Androcur , but also Luteran , Lotényl , and other progestins;
- a lack of recognition, given the little visibility of our victims , even if a clear improvement has taken place in the past two months;
- the problem of the real number of victims , many neurosurgeonians who have operated for 10 years, without ever making their patients and health authorities the link between meningiomas and hormonal treatments;
- Problems of access to compensation for victims.
The associations present or represented were: APESAC ( Dépakine), the victims of Stevens - Johnson ( syndrome , Les Filles des, the French Association of Thyroid patients, associations of vaccine victims, Resist (Implant Essure) and the association of victims of the finasteride.
At the end of this round table, together there is a conference at the start of the school year, in order to envisage common actions. In conclusion, faced with other associations present in the landscape of health scandals for many years, it is necessary to take common actions, between independent associations and having no connection with the pharmaceutical industry, and does not live any public funds.
The fight continues for the hundreds of women (thousands?) Of victims of meningiomas in France who have suffered, who suffer and who potentially undergo terrible side effects, ranging from simple occasional discomfort to disabling suffering and heavy surgical operations, even on death.
And the fight also continues for women whose information still does not reach them, and who continue to take these treatments without knowing the potentially serious effects.
To date, it appears obvious that we still have a lot of work.
Find the other Amavea articles here
